5 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital

3. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Maverick Capital’s Stake Value: $140 million

Percentage of Maverick Capital’s 13F Portfolio: 1.41%

Number of Hedge Fund Holders: 17

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is developing treatments for patients suffering from cancer, immune system, and viral diseases. Its medicines target solid tumors, hematologic malignancies, and multiple sclerosis, among others.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) raked in $5 million in revenue and -$0.90 in GAAP EPS for its fiscal Q3, beating analyst estimates for both. Stifel reduced its price target to $27 from $30 in October 2021.

Mr. Ainslie’s hedge fund had a stake of $140 million in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) through holding 7.8 million shares. It represented 1.41% of its portfolio during Q3 2021. During the same time period, 17 of the 867 hedge funds polled by Insider Monkey also held a stake in the medical firm.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s largest investor is Seth Klarman’s Baupost Group who owns 8.4 million shares worth $151 million.